The DOI matches its Crossref record.
Prostaglandin E Receptor EP4 Antagonism Inhibits Breast Cancer Metastasis
Open accessAbstract
Cyclooxygenase-2 (COX-2) expression in epithelial tumors is frequently associated with a poor prognosis. In a murine model of metastatic breast cancer, we showed that COX-2 inhibition is associated with decreased metastatic capacity. The COX-2 product, prostaglandin E2 (PGE2), acts through a family of G protein–coupled receptors designated EP1-4 that mediate intracellular signaling by multiple pathways. We characterized EP receptor expression on three murine mammary tumor cell lines and show that all four EP isoforms were detected in each cell. Stimulation of cells with either PGE2 or the selective EP4/EP2 agonist PGE1-OH resulted in increased intracellular cyclic AMP and this response was inhibited with either EP2 or EP4 antagonists. Nothing is known about the function of EP receptors in tumor metastasis. We tested the hypothesis that the prevention of EP receptor signaling would, like inhibition of PGE2 synthesis, inhibit tumor metastasis. Our results show for the first time that antagonism of the EP4 receptor with either AH23848 or ONO-AE3-208 reduced metastasis as compared with vehicle-treated controls. The therapeutic effect was comparable to that observed with the dual COX-1/COX-2 inhibitor indomethacin. EP3 antagonism had no effect on tumor metastasis. Mammary tumor cells migrated in vitro in response to PGE2 and this chemotactic response was blocked by EP receptor antagonists. Likewise, the proliferation of tumor cells was also directly inhibited by antagonists of either EP4 or EP1/EP2. These studies support the hypothesis that EP receptor antagonists may be an alternative approach to the use of COX inhibitors to prevent tumor metastasis. (Cancer Res 2006; 66(6): 2923-7)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Prostaglandin E2 Promotes Tumor Progression by Inducing Myeloid-Derived Suppressor Cells
Sinha, P., Clements, V. K., Fulton, A. M., & Ostrand-Rosenberg, S. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4174 · Cited by 755
Self-citationWoodward, D. F., Jones, R. L., & Narumiya, S. (2011) · Pharmacological Reviews · doi:10.1124/pr.110.003517 · Cited by 443
NSAIDs and Cancer Prevention: Targets Downstream of COX-2
Cha, Y. I., & DuBois, R. N. (2007) · Annual Review of Medicine · doi:10.1146/annurev.med.57.121304.131253 · Cited by 308
Prostaglandin E2 and Cancer: Insight into Tumor Progression and Immunity
Finetti, F., Travelli, C., Ercoli, J., Colombo, G., Buoso, E., & Trabalzini, L. (2020) · Biology · doi:10.3390/biology9120434 · Cited by 302
The Prostanoid EP4 Receptor and Its Signaling Pathway
Yokoyama, U., Iwatsubo, K., Umemura, M., Fujita, T., & Ishikawa, Y. (2013) · Pharmacological Reviews · doi:10.1124/pr.112.007195 · Cited by 264
Metadata
- Authors
- Ma, X., Kundu, N., Rifat, S., Walser, T., & Fulton, A. M.
- Venue
- Cancer Research
- Published
- 2006-03-15
- Volume
- 66
- Issue
- 6
- Pages
- 2923-2927
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W1985446725
- Cited by
- 160
- References
- 0
- FWCI
- 7.36
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Prostaglandin E Receptor EP4 Antagonism Inhibits Breast Cancer Metastasis. https://app.cochat.ai/papers/10.1158/0008-5472.can-05-4348
- The paper
- Ma, X., Kundu, N., Rifat, S., Walser, T., & Fulton, A. M. (2006). Prostaglandin E Receptor EP4 Antagonism Inhibits Breast Cancer Metastasis. Cancer Research. https://doi.org/10.1158/0008-5472.can-05-4348
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.